RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Previous research has confirmed that hemorrhage is among the most commonly encountered
pregnancy complications in the Tibet Autonomous Region (TAR). This trial will test the
effectiveness of a traditional Tibetan drug (Zhi Byed 11) vs. misoprostol to prevent
postpartum hemorrhage (PPH) among women delivering vaginally in three hospitals in Lhasa,
TAR.
Phase:
N/A
Details
Lead Sponsor:
NICHD Global Network for Women's and Children's Health
Collaborators:
Bill and Melinda Gates Foundation Fogarty International Center of the National Institute of Health Global Network for Women's and Children's Health Research Health Bureau Tibet Autonomous Region John E. Fogarty International Center (FIC) National Cancer Institute (NCI) National Center for Complementary and Integrative Health (NCCIH) National Institute of Dental and Craniofacial Research (NIDCR) One Heart Project RTI International University of California, San Francisco University of Utah